Cellectis (NASDAQ:CLLS) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Cellectis (NASDAQ:CLLS) from a buy rating to a strong-buy rating in a research note released on Thursday, January 4th.

Several other analysts also recently weighed in on the stock. Jefferies Group reiterated a buy rating and issued a $47.00 price objective on shares of Cellectis in a research report on Sunday, October 29th. Zacks Investment Research upgraded shares of Cellectis from a sell rating to a hold rating and set a $36.00 price objective on the stock in a research report on Tuesday, October 24th. ValuEngine downgraded shares of Cellectis from a hold rating to a sell rating in a research report on Friday, December 1st. Nomura cut their price objective on shares of Cellectis from $49.00 to $43.00 and set a buy rating on the stock in a research report on Wednesday, September 6th. Finally, SunTrust Banks reissued a hold rating and set a $20.00 target price on shares of Cellectis in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $39.29.

Cellectis (NASDAQ:CLLS) traded down $0.70 during trading on Thursday, hitting $29.06. 157,400 shares of the stock were exchanged, compared to its average volume of 138,512. The company has a market cap of $1,060.00 and a P/E ratio of -10.64. Cellectis has a one year low of $17.25 and a one year high of $35.07.

A number of institutional investors have recently added to or reduced their stakes in CLLS. Balyasny Asset Management LLC acquired a new position in shares of Cellectis in the 2nd quarter worth approximately $719,000. Advisors Asset Management Inc. boosted its holdings in shares of Cellectis by 1,501.1% in the third quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock worth $643,000 after buying an additional 21,181 shares during the period. Sphera Funds Management LTD. boosted its holdings in shares of Cellectis by 71.1% in the third quarter. Sphera Funds Management LTD. now owns 348,736 shares of the biotechnology company’s stock worth $9,922,000 after buying an additional 144,972 shares during the period. KBC Group NV acquired a new position in shares of Cellectis in the third quarter worth about $366,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after buying an additional 5,435 shares during the period. 16.35% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/01/12/cellectis-clls-upgraded-by-bidaskclub-to-strong-buy.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply